img

Global Semi-solid Dosage Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Semi-solid Dosage Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

The global Semi-solid Dosage market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Semi-solid Dosage is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Semi-solid Dosage is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Semi-solid Dosage is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Semi-solid Dosage include Johnson & Johnson, Merck & Co, Bayer AG, Hisamitsu Pharmaceutical, Glenmark Pharmaceuticals, Cipla Ltd, Nestle SA, Novartis AG and GlaxoSmithKline plc, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Semi-solid Dosage, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Semi-solid Dosage by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Semi-solid Dosage market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Semi-solid Dosage market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Johnson & Johnson
Merck & Co
Bayer AG
Hisamitsu Pharmaceutical
Glenmark Pharmaceuticals
Cipla Ltd
Nestle SA
Novartis AG
GlaxoSmithKline plc
Bausch Health Companies
Allergan
Biofrontera
Crown Laboratories
Akorn
Ingenus Pharmaceuticals
Sun Pharmaceuticals
Crescita Therapeutics
Mylan N.V.
Encore Dermatology
LEO Pharma
Almirall, S.A
Aclaris Therapeutics
Taro Pharmaceutical Industries
Teligent Pharma
Perrigo Pharma
By Type
Ointment
Paste
Plaster
Gel
By Application
Skin
Nasal Cavity
Vaginal Cavity
Rectal Cavity
Other
Sales by Region
North America
United States
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Semi-solid Dosage in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Semi-solid Dosage manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Semi-solid Dosage sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Semi-solid Dosage Definition
1.2 Market by Type
1.2.1 Global Semi-solid Dosage Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 Ointment
1.2.3 Paste
1.2.4 Plaster
1.2.5 Gel
1.3 Market Segment by Application
1.3.1 Global Semi-solid Dosage Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Skin
1.3.3 Nasal Cavity
1.3.4 Vaginal Cavity
1.3.5 Rectal Cavity
1.3.6 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Semi-solid Dosage Sales
2.1 Global Semi-solid Dosage Revenue Estimates and Forecasts 2018-2034
2.2 Global Semi-solid Dosage Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Semi-solid Dosage Revenue by Region
2.3.1 Global Semi-solid Dosage Revenue by Region (2018-2024)
2.3.2 Global Semi-solid Dosage Revenue by Region (2024-2034)
2.4 Global Semi-solid Dosage Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Semi-solid Dosage Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Semi-solid Dosage Sales Quantity by Region
2.6.1 Global Semi-solid Dosage Sales Quantity by Region (2018-2024)
2.6.2 Global Semi-solid Dosage Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Semi-solid Dosage Sales Quantity by Manufacturers
3.1.1 Global Semi-solid Dosage Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Semi-solid Dosage Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Semi-solid Dosage Sales in 2022
3.2 Global Semi-solid Dosage Revenue by Manufacturers
3.2.1 Global Semi-solid Dosage Revenue by Manufacturers (2018-2024)
3.2.2 Global Semi-solid Dosage Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Semi-solid Dosage Revenue in 2022
3.3 Global Semi-solid Dosage Sales Price by Manufacturers
3.4 Global Key Players of Semi-solid Dosage, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Semi-solid Dosage Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Semi-solid Dosage, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Semi-solid Dosage, Product Offered and Application
3.8 Global Key Manufacturers of Semi-solid Dosage, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Semi-solid Dosage Sales Quantity by Type
4.1.1 Global Semi-solid Dosage Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Semi-solid Dosage Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Semi-solid Dosage Sales Quantity Market Share by Type (2018-2034)
4.2 Global Semi-solid Dosage Revenue by Type
4.2.1 Global Semi-solid Dosage Historical Revenue by Type (2018-2024)
4.2.2 Global Semi-solid Dosage Forecasted Revenue by Type (2024-2034)
4.2.3 Global Semi-solid Dosage Revenue Market Share by Type (2018-2034)
4.3 Global Semi-solid Dosage Price by Type
4.3.1 Global Semi-solid Dosage Price by Type (2018-2024)
4.3.2 Global Semi-solid Dosage Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Semi-solid Dosage Sales Quantity by Application
5.1.1 Global Semi-solid Dosage Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Semi-solid Dosage Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Semi-solid Dosage Sales Quantity Market Share by Application (2018-2034)
5.2 Global Semi-solid Dosage Revenue by Application
5.2.1 Global Semi-solid Dosage Historical Revenue by Application (2018-2024)
5.2.2 Global Semi-solid Dosage Forecasted Revenue by Application (2024-2034)
5.2.3 Global Semi-solid Dosage Revenue Market Share by Application (2018-2034)
5.3 Global Semi-solid Dosage Price by Application
5.3.1 Global Semi-solid Dosage Price by Application (2018-2024)
5.3.2 Global Semi-solid Dosage Price Forecast by Application (2024-2034)
6 North America
6.1 North America Semi-solid Dosage Sales by Company
6.1.1 North America Semi-solid Dosage Revenue by Company (2018-2024)
6.1.2 North America Semi-solid Dosage Sales Quantity by Company (2018-2024)
6.2 North America Semi-solid Dosage Market Size by Type
6.2.1 North America Semi-solid Dosage Sales Quantity by Type (2018-2034)
6.2.2 North America Semi-solid Dosage Revenue by Type (2018-2034)
6.3 North America Semi-solid Dosage Market Size by Application
6.3.1 North America Semi-solid Dosage Sales Quantity by Application (2018-2034)
6.3.2 North America Semi-solid Dosage Revenue by Application (2018-2034)
6.4 North America Semi-solid Dosage Market Size by Country
6.4.1 North America Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Semi-solid Dosage Revenue by Country (2018-2034)
6.4.3 North America Semi-solid Dosage Sales Quantity by Country (2018-2034)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Semi-solid Dosage Sales by Company
7.1.1 Europe Semi-solid Dosage Sales Quantity by Company (2018-2024)
7.1.2 Europe Semi-solid Dosage Revenue by Company (2018-2024)
7.2 Europe Semi-solid Dosage Market Size by Type
7.2.1 Europe Semi-solid Dosage Sales Quantity by Type (2018-2034)
7.2.2 Europe Semi-solid Dosage Revenue by Type (2018-2034)
7.3 Europe Semi-solid Dosage Market Size by Application
7.3.1 Europe Semi-solid Dosage Sales Quantity by Application (2018-2034)
7.3.2 Europe Semi-solid Dosage Revenue by Application (2018-2034)
7.4 Europe Semi-solid Dosage Market Size by Country
7.4.1 Europe Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Semi-solid Dosage Revenue by Country (2018-2034)
7.4.3 Europe Semi-solid Dosage Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Semi-solid Dosage Sales by Company
8.1.1 China Semi-solid Dosage Sales Quantity by Company (2018-2024)
8.1.2 China Semi-solid Dosage Revenue by Company (2018-2024)
8.2 China Semi-solid Dosage Market Size by Type
8.2.1 China Semi-solid Dosage Sales Quantity by Type (2018-2034)
8.2.2 China Semi-solid Dosage Revenue by Type (2018-2034)
8.3 China Semi-solid Dosage Market Size by Application
8.3.1 China Semi-solid Dosage Sales Quantity by Application (2018-2034)
8.3.2 China Semi-solid Dosage Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Semi-solid Dosage Sales by Company
9.1.1 APAC Semi-solid Dosage Sales Quantity by Company (2018-2024)
9.1.2 APAC Semi-solid Dosage Revenue by Company (2018-2024)
9.2 APAC Semi-solid Dosage Market Size by Type
9.2.1 APAC Semi-solid Dosage Sales Quantity by Type (2018-2034)
9.2.2 APAC Semi-solid Dosage Revenue by Type (2018-2034)
9.3 APAC Semi-solid Dosage Market Size by Application
9.3.1 APAC Semi-solid Dosage Sales Quantity by Application (2018-2034)
9.3.2 APAC Semi-solid Dosage Revenue by Application (2018-2034)
9.4 APAC Semi-solid Dosage Market Size by Region
9.4.1 APAC Semi-solid Dosage Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Semi-solid Dosage Revenue by Region (2018-2034)
9.4.3 APAC Semi-solid Dosage Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Semi-solid Dosage Sales by Company
10.1.1 Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Semi-solid Dosage Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Semi-solid Dosage Market Size by Type
10.2.1 Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Semi-solid Dosage Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Semi-solid Dosage Market Size by Application
10.3.1 Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Semi-solid Dosage Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Semi-solid Dosage Market Size by Country
10.4.1 Middle East, Africa and Latin America Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Semi-solid Dosage Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Johnson & Johnson
11.1.1 Johnson & Johnson Company Information
11.1.2 Johnson & Johnson Overview
11.1.3 Johnson & Johnson Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Johnson & Johnson Semi-solid Dosage Products and Services
11.1.5 Johnson & Johnson Semi-solid Dosage SWOT Analysis
11.1.6 Johnson & Johnson Recent Developments
11.2 Merck & Co
11.2.1 Merck & Co Company Information
11.2.2 Merck & Co Overview
11.2.3 Merck & Co Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Merck & Co Semi-solid Dosage Products and Services
11.2.5 Merck & Co Semi-solid Dosage SWOT Analysis
11.2.6 Merck & Co Recent Developments
11.3 Bayer AG
11.3.1 Bayer AG Company Information
11.3.2 Bayer AG Overview
11.3.3 Bayer AG Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Bayer AG Semi-solid Dosage Products and Services
11.3.5 Bayer AG Semi-solid Dosage SWOT Analysis
11.3.6 Bayer AG Recent Developments
11.4 Hisamitsu Pharmaceutical
11.4.1 Hisamitsu Pharmaceutical Company Information
11.4.2 Hisamitsu Pharmaceutical Overview
11.4.3 Hisamitsu Pharmaceutical Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Hisamitsu Pharmaceutical Semi-solid Dosage Products and Services
11.4.5 Hisamitsu Pharmaceutical Semi-solid Dosage SWOT Analysis
11.4.6 Hisamitsu Pharmaceutical Recent Developments
11.5 Glenmark Pharmaceuticals
11.5.1 Glenmark Pharmaceuticals Company Information
11.5.2 Glenmark Pharmaceuticals Overview
11.5.3 Glenmark Pharmaceuticals Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Glenmark Pharmaceuticals Semi-solid Dosage Products and Services
11.5.5 Glenmark Pharmaceuticals Semi-solid Dosage SWOT Analysis
11.5.6 Glenmark Pharmaceuticals Recent Developments
11.6 Cipla Ltd
11.6.1 Cipla Ltd Company Information
11.6.2 Cipla Ltd Overview
11.6.3 Cipla Ltd Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Cipla Ltd Semi-solid Dosage Products and Services
11.6.5 Cipla Ltd Semi-solid Dosage SWOT Analysis
11.6.6 Cipla Ltd Recent Developments
11.7 Nestle SA
11.7.1 Nestle SA Company Information
11.7.2 Nestle SA Overview
11.7.3 Nestle SA Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Nestle SA Semi-solid Dosage Products and Services
11.7.5 Nestle SA Semi-solid Dosage SWOT Analysis
11.7.6 Nestle SA Recent Developments
11.8 Novartis AG
11.8.1 Novartis AG Company Information
11.8.2 Novartis AG Overview
11.8.3 Novartis AG Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 Novartis AG Semi-solid Dosage Products and Services
11.8.5 Novartis AG Semi-solid Dosage SWOT Analysis
11.8.6 Novartis AG Recent Developments
11.9 GlaxoSmithKline plc
11.9.1 GlaxoSmithKline plc Company Information
11.9.2 GlaxoSmithKline plc Overview
11.9.3 GlaxoSmithKline plc Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 GlaxoSmithKline plc Semi-solid Dosage Products and Services
11.9.5 GlaxoSmithKline plc Semi-solid Dosage SWOT Analysis
11.9.6 GlaxoSmithKline plc Recent Developments
11.10 Bausch Health Companies
11.10.1 Bausch Health Companies Company Information
11.10.2 Bausch Health Companies Overview
11.10.3 Bausch Health Companies Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Bausch Health Companies Semi-solid Dosage Products and Services
11.10.5 Bausch Health Companies Semi-solid Dosage SWOT Analysis
11.10.6 Bausch Health Companies Recent Developments
11.11 Allergan
11.11.1 Allergan Company Information
11.11.2 Allergan Overview
11.11.3 Allergan Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 Allergan Semi-solid Dosage Products and Services
11.11.5 Allergan Recent Developments
11.12 Biofrontera
11.12.1 Biofrontera Company Information
11.12.2 Biofrontera Overview
11.12.3 Biofrontera Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.12.4 Biofrontera Semi-solid Dosage Products and Services
11.12.5 Biofrontera Recent Developments
11.13 Crown Laboratories
11.13.1 Crown Laboratories Company Information
11.13.2 Crown Laboratories Overview
11.13.3 Crown Laboratories Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.13.4 Crown Laboratories Semi-solid Dosage Products and Services
11.13.5 Crown Laboratories Recent Developments
11.14 Akorn
11.14.1 Akorn Company Information
11.14.2 Akorn Overview
11.14.3 Akorn Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.14.4 Akorn Semi-solid Dosage Products and Services
11.14.5 Akorn Recent Developments
11.15 Ingenus Pharmaceuticals
11.15.1 Ingenus Pharmaceuticals Company Information
11.15.2 Ingenus Pharmaceuticals Overview
11.15.3 Ingenus Pharmaceuticals Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.15.4 Ingenus Pharmaceuticals Semi-solid Dosage Products and Services
11.15.5 Ingenus Pharmaceuticals Recent Developments
11.16 Sun Pharmaceuticals
11.16.1 Sun Pharmaceuticals Company Information
11.16.2 Sun Pharmaceuticals Overview
11.16.3 Sun Pharmaceuticals Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.16.4 Sun Pharmaceuticals Semi-solid Dosage Products and Services
11.16.5 Sun Pharmaceuticals Recent Developments
11.17 Crescita Therapeutics
11.17.1 Crescita Therapeutics Company Information
11.17.2 Crescita Therapeutics Overview
11.17.3 Crescita Therapeutics Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.17.4 Crescita Therapeutics Semi-solid Dosage Products and Services
11.17.5 Crescita Therapeutics Recent Developments
11.18 Mylan N.V.
11.18.1 Mylan N.V. Company Information
11.18.2 Mylan N.V. Overview
11.18.3 Mylan N.V. Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.18.4 Mylan N.V. Semi-solid Dosage Products and Services
11.18.5 Mylan N.V. Recent Developments
11.19 Encore Dermatology
11.19.1 Encore Dermatology Company Information
11.19.2 Encore Dermatology Overview
11.19.3 Encore Dermatology Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.19.4 Encore Dermatology Semi-solid Dosage Products and Services
11.19.5 Encore Dermatology Recent Developments
11.20 LEO Pharma
11.20.1 LEO Pharma Company Information
11.20.2 LEO Pharma Overview
11.20.3 LEO Pharma Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.20.4 LEO Pharma Semi-solid Dosage Products and Services
11.20.5 LEO Pharma Recent Developments
11.21 Almirall, S.A
11.21.1 Almirall, S.A Company Information
11.21.2 Almirall, S.A Overview
11.21.3 Almirall, S.A Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.21.4 Almirall, S.A Semi-solid Dosage Products and Services
11.21.5 Almirall, S.A Recent Developments
11.22 Aclaris Therapeutics
11.22.1 Aclaris Therapeutics Company Information
11.22.2 Aclaris Therapeutics Overview
11.22.3 Aclaris Therapeutics Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.22.4 Aclaris Therapeutics Semi-solid Dosage Products and Services
11.22.5 Aclaris Therapeutics Recent Developments
11.23 Taro Pharmaceutical Industries
11.23.1 Taro Pharmaceutical Industries Company Information
11.23.2 Taro Pharmaceutical Industries Overview
11.23.3 Taro Pharmaceutical Industries Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.23.4 Taro Pharmaceutical Industries Semi-solid Dosage Products and Services
11.23.5 Taro Pharmaceutical Industries Recent Developments
11.24 Teligent Pharma
11.24.1 Teligent Pharma Company Information
11.24.2 Teligent Pharma Overview
11.24.3 Teligent Pharma Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.24.4 Teligent Pharma Semi-solid Dosage Products and Services
11.24.5 Teligent Pharma Recent Developments
11.25 Perrigo Pharma
11.25.1 Perrigo Pharma Company Information
11.25.2 Perrigo Pharma Overview
11.25.3 Perrigo Pharma Semi-solid Dosage Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.25.4 Perrigo Pharma Semi-solid Dosage Products and Services
11.25.5 Perrigo Pharma Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Semi-solid Dosage Value Chain Analysis
12.2 Semi-solid Dosage Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Semi-solid Dosage Production Mode & Process
12.4 Semi-solid Dosage Sales and Marketing
12.4.1 Semi-solid Dosage Sales Channels
12.4.2 Semi-solid Dosage Distributors
12.5 Semi-solid Dosage Customers
13 Market Dynamics
13.1 Semi-solid Dosage Industry Trends
13.2 Semi-solid Dosage Market Drivers
13.3 Semi-solid Dosage Market Challenges
13.4 Semi-solid Dosage Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Semi-solid Dosage Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Ointment
Table 3. Major Manufacturers of Paste
Table 4. Major Manufacturers of Plaster
Table 5. Major Manufacturers of Gel
Table 6. Global Semi-solid Dosage Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Semi-solid Dosage Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 8. Global Semi-solid Dosage Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Semi-solid Dosage Revenue Market Share by Region (2018-2024)
Table 10. Global Semi-solid Dosage Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Semi-solid Dosage Revenue Market Share by Region (2024-2034)
Table 12. Global Semi-solid Dosage Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 13. Global Semi-solid Dosage Sales by Region (2018-2024) & (K Units)
Table 14. Global Semi-solid Dosage Sales Market Share by Region (2018-2024)
Table 15. Global Semi-solid Dosage Sales by Region (2024-2034) & (K Units)
Table 16. Global Semi-solid Dosage Sales Market Share by Region (2024-2034)
Table 17. Global Semi-solid Dosage Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 18. Global Semi-solid Dosage Sales Quantity Share by Manufacturers (2018-2024)
Table 19. Global Semi-solid Dosage Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Semi-solid Dosage Revenue Share by Manufacturers (2018-2024)
Table 21. Global Semi-solid Dosage Price by Manufacturers 2018-2024 (USD/Unit)
Table 22. Global Key Players of Semi-solid Dosage, Industry Ranking, 2021 VS 2022
Table 23. Global Semi-solid Dosage Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Semi-solid Dosage by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Semi-solid Dosage as of 2022)
Table 25. Global Key Manufacturers of Semi-solid Dosage, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Semi-solid Dosage, Product Offered and Application
Table 27. Global Key Manufacturers of Semi-solid Dosage, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Semi-solid Dosage Sales Quantity by Type (2018-2024) & (K Units)
Table 30. Global Semi-solid Dosage Sales Quantity by Type (2024-2034) & (K Units)
Table 31. Global Semi-solid Dosage Sales Quantity Share by Type (2018-2024)
Table 32. Global Semi-solid Dosage Sales Quantity Share by Type (2024-2034)
Table 33. Global Semi-solid Dosage Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Semi-solid Dosage Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Semi-solid Dosage Revenue Share by Type (2018-2024)
Table 36. Global Semi-solid Dosage Revenue Share by Type (2024-2034)
Table 37. Semi-solid Dosage Price by Type (2018-2024) & (USD/Unit)
Table 38. Global Semi-solid Dosage Price Forecast by Type (2024-2034) & (USD/Unit)
Table 39. Global Semi-solid Dosage Sales Quantity by Application (2018-2024) & (K Units)
Table 40. Global Semi-solid Dosage Sales Quantity by Application (2024-2034) & (K Units)
Table 41. Global Semi-solid Dosage Sales Quantity Share by Application (2018-2024)
Table 42. Global Semi-solid Dosage Sales Quantity Share by Application (2024-2034)
Table 43. Global Semi-solid Dosage Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Semi-solid Dosage Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Semi-solid Dosage Revenue Share by Application (2018-2024)
Table 46. Global Semi-solid Dosage Revenue Share by Application (2024-2034)
Table 47. Semi-solid Dosage Price by Application (2018-2024) & (USD/Unit)
Table 48. Global Semi-solid Dosage Price Forecast by Application (2024-2034) & (USD/Unit)
Table 49. North America Semi-solid Dosage Revenue by Company (2018-2024) & (US$ Million)
Table 50. North America Semi-solid Dosage Sales Quantity by Company (2018-2024) & (K Units)
Table 51. North America Semi-solid Dosage Sales Quantity by Type (2018-2024) & (K Units)
Table 52. North America Semi-solid Dosage Sales Quantity by Type (2024-2034) & (K Units)
Table 53. North America Semi-solid Dosage Revenue by Type (2018-2024) & (US$ Million)
Table 54. North America Semi-solid Dosage Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Semi-solid Dosage Sales Quantity by Application (2018-2024) & (K Units)
Table 56. North America Semi-solid Dosage Sales Quantity by Application (2024-2034) & (K Units)
Table 57. North America Semi-solid Dosage Revenue by Application (2018-2024) & (US$ Million)
Table 58. North America Semi-solid Dosage Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 60. North America Semi-solid Dosage Revenue by Country (2018-2024) & (US$ Million)
Table 61. North America Semi-solid Dosage Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Semi-solid Dosage Sales Quantity by Country (2018-2024) & (K Units)
Table 63. North America Semi-solid Dosage Sales Quantity by Country (2024-2034) & (K Units)
Table 64. Europe Semi-solid Dosage Sales Quantity by Company (2018-2024) & (K Units)
Table 65. Europe Semi-solid Dosage Revenue by Company (2018-2024) & (US$ Million)
Table 66. Europe Semi-solid Dosage Sales Quantity by Type (2018-2024) & (K Units)
Table 67. Europe Semi-solid Dosage Sales Quantity by Type (2024-2034) & (K Units)
Table 68. Europe Semi-solid Dosage Revenue by Type (2018-2024) & (US$ Million)
Table 69. Europe Semi-solid Dosage Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Semi-solid Dosage Sales Quantity by Application (2018-2024) & (K Units)
Table 71. Europe Semi-solid Dosage Sales Quantity by Application (2024-2034) & (K Units)
Table 72. Europe Semi-solid Dosage Revenue by Application (2018-2024) & (US$ Million)
Table 73. Europe Semi-solid Dosage Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 75. Europe Semi-solid Dosage Revenue by Country (2018-2024) & (US$ Million)
Table 76. Europe Semi-solid Dosage Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Semi-solid Dosage Sales Quantity by Country (2018-2024) & (K Units)
Table 78. Europe Semi-solid Dosage Sales Quantity by Country (2024-2034) & (K Units)
Table 79. China Semi-solid Dosage Sales Quantity by Company (2018-2024) & (K Units)
Table 80. China Semi-solid Dosage Revenue by Company (2018-2024) & (US$ Million)
Table 81. China Semi-solid Dosage Sales Quantity by Type (2018-2024) & (K Units)
Table 82. China Semi-solid Dosage Sales Quantity by Type (2024-2034) & (K Units)
Table 83. China Semi-solid Dosage Revenue by Type (2018-2024) & (US$ Million)
Table 84. China Semi-solid Dosage Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Semi-solid Dosage Sales Quantity by Application (2018-2024) & (K Units)
Table 86. China Semi-solid Dosage Sales Quantity by Application (2024-2034) & (K Units)
Table 87. China Semi-solid Dosage Revenue by Application (2018-2024) & (US$ Million)
Table 88. China Semi-solid Dosage Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Semi-solid Dosage Sales Quantity by Company (2018-2024) & (K Units)
Table 90. APAC Semi-solid Dosage Revenue by Company (2018-2024) & (US$ Million)
Table 91. APAC Semi-solid Dosage Sales Quantity by Type (2018-2024) & (K Units)
Table 92. APAC Semi-solid Dosage Sales Quantity by Type (2024-2034) & (K Units)
Table 93. APAC Semi-solid Dosage Revenue by Type (2018-2024) & (US$ Million)
Table 94. APAC Semi-solid Dosage Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Semi-solid Dosage Sales Quantity by Application (2018-2024) & (K Units)
Table 96. APAC Semi-solid Dosage Sales Quantity by Application (2024-2034) & (K Units)
Table 97. APAC Semi-solid Dosage Revenue by Application (2018-2024) & (US$ Million)
Table 98. APAC Semi-solid Dosage Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Semi-solid Dosage Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 100. APAC Semi-solid Dosage Revenue by Region (2018-2024) & (US$ Million)
Table 101. APAC Semi-solid Dosage Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Semi-solid Dosage Sales Quantity by Region (2018-2024) & (K Units)
Table 103. APAC Semi-solid Dosage Sales Quantity by Region (2024-2034) & (K Units)
Table 104. Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity by Company (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Semi-solid Dosage Revenue by Company (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity by Type (2018-2024) & (K Units)
Table 107. Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity by Type (2024-2034) & (K Units)
Table 108. Middle East, Africa and Latin America Semi-solid Dosage Revenue by Type (2018-2024) & (US$ Million)
Table 109. Middle East, Africa and Latin America Semi-solid Dosage Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity by Application (2018-2024) & (K Units)
Table 111. Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity by Application (2024-2034) & (K Units)
Table 112. Middle East, Africa and Latin America Semi-solid Dosage Revenue by Application (2018-2024) & (US$ Million)
Table 113. Middle East, Africa and Latin America Semi-solid Dosage Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Semi-solid Dosage Revenue by Country (2018-2024) & (US$ Million)
Table 116. Middle East, Africa and Latin America Semi-solid Dosage Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity by Country (2018-2024) & (K Units)
Table 118. Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity by Country (2024-2034) & (K Units)
Table 119. Johnson & Johnson Company Information
Table 120. Johnson & Johnson Description and Overview
Table 121. Johnson & Johnson Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 122. Johnson & Johnson Semi-solid Dosage Product and Services
Table 123. Johnson & Johnson Semi-solid Dosage SWOT Analysis
Table 124. Johnson & Johnson Recent Developments
Table 125. Merck & Co Company Information
Table 126. Merck & Co Description and Overview
Table 127. Merck & Co Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 128. Merck & Co Semi-solid Dosage Product and Services
Table 129. Merck & Co Semi-solid Dosage SWOT Analysis
Table 130. Merck & Co Recent Developments
Table 131. Bayer AG Company Information
Table 132. Bayer AG Description and Overview
Table 133. Bayer AG Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 134. Bayer AG Semi-solid Dosage Product and Services
Table 135. Bayer AG Semi-solid Dosage SWOT Analysis
Table 136. Bayer AG Recent Developments
Table 137. Hisamitsu Pharmaceutical Company Information
Table 138. Hisamitsu Pharmaceutical Description and Overview
Table 139. Hisamitsu Pharmaceutical Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 140. Hisamitsu Pharmaceutical Semi-solid Dosage Product and Services
Table 141. Hisamitsu Pharmaceutical Semi-solid Dosage SWOT Analysis
Table 142. Hisamitsu Pharmaceutical Recent Developments
Table 143. Glenmark Pharmaceuticals Company Information
Table 144. Glenmark Pharmaceuticals Description and Overview
Table 145. Glenmark Pharmaceuticals Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 146. Glenmark Pharmaceuticals Semi-solid Dosage Product and Services
Table 147. Glenmark Pharmaceuticals Semi-solid Dosage SWOT Analysis
Table 148. Glenmark Pharmaceuticals Recent Developments
Table 149. Cipla Ltd Company Information
Table 150. Cipla Ltd Description and Overview
Table 151. Cipla Ltd Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 152. Cipla Ltd Semi-solid Dosage Product and Services
Table 153. Cipla Ltd Semi-solid Dosage SWOT Analysis
Table 154. Cipla Ltd Recent Developments
Table 155. Nestle SA Company Information
Table 156. Nestle SA Description and Overview
Table 157. Nestle SA Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 158. Nestle SA Semi-solid Dosage Product and Services
Table 159. Nestle SA Semi-solid Dosage SWOT Analysis
Table 160. Nestle SA Recent Developments
Table 161. Novartis AG Company Information
Table 162. Novartis AG Description and Overview
Table 163. Novartis AG Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 164. Novartis AG Semi-solid Dosage Product and Services
Table 165. Novartis AG Semi-solid Dosage SWOT Analysis
Table 166. Novartis AG Recent Developments
Table 167. GlaxoSmithKline plc Company Information
Table 168. GlaxoSmithKline plc Description and Overview
Table 169. GlaxoSmithKline plc Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 170. GlaxoSmithKline plc Semi-solid Dosage Product and Services
Table 171. GlaxoSmithKline plc Semi-solid Dosage SWOT Analysis
Table 172. GlaxoSmithKline plc Recent Developments
Table 173. Bausch Health Companies Company Information
Table 174. Bausch Health Companies Description and Overview
Table 175. Bausch Health Companies Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 176. Bausch Health Companies Semi-solid Dosage Product and Services
Table 177. Bausch Health Companies Semi-solid Dosage SWOT Analysis
Table 178. Bausch Health Companies Recent Developments
Table 179. Allergan Company Information
Table 180. Allergan Description and Overview
Table 181. Allergan Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 182. Allergan Semi-solid Dosage Product and Services
Table 183. Allergan Recent Developments
Table 184. Biofrontera Company Information
Table 185. Biofrontera Description and Overview
Table 186. Biofrontera Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 187. Biofrontera Semi-solid Dosage Product and Services
Table 188. Biofrontera Recent Developments
Table 189. Crown Laboratories Company Information
Table 190. Crown Laboratories Description and Overview
Table 191. Crown Laboratories Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 192. Crown Laboratories Semi-solid Dosage Product and Services
Table 193. Crown Laboratories Recent Developments
Table 194. Akorn Company Information
Table 195. Akorn Description and Overview
Table 196. Akorn Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 197. Akorn Semi-solid Dosage Product and Services
Table 198. Akorn Recent Developments
Table 199. Ingenus Pharmaceuticals Company Information
Table 200. Ingenus Pharmaceuticals Description and Overview
Table 201. Ingenus Pharmaceuticals Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 202. Ingenus Pharmaceuticals Semi-solid Dosage Product and Services
Table 203. Ingenus Pharmaceuticals Recent Developments
Table 204. Sun Pharmaceuticals Company Information
Table 205. Sun Pharmaceuticals Description and Overview
Table 206. Sun Pharmaceuticals Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 207. Sun Pharmaceuticals Semi-solid Dosage Product and Services
Table 208. Sun Pharmaceuticals Recent Developments
Table 209. Crescita Therapeutics Company Information
Table 210. Crescita Therapeutics Description and Overview
Table 211. Crescita Therapeutics Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 212. Crescita Therapeutics Semi-solid Dosage Product and Services
Table 213. Crescita Therapeutics Recent Developments
Table 214. Mylan N.V. Company Information
Table 215. Mylan N.V. Description and Overview
Table 216. Mylan N.V. Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 217. Mylan N.V. Semi-solid Dosage Product and Services
Table 218. Mylan N.V. Recent Developments
Table 219. Encore Dermatology Company Information
Table 220. Encore Dermatology Description and Overview
Table 221. Encore Dermatology Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 222. Encore Dermatology Semi-solid Dosage Product and Services
Table 223. Encore Dermatology Recent Developments
Table 224. LEO Pharma Company Information
Table 225. LEO Pharma Description and Overview
Table 226. LEO Pharma Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 227. LEO Pharma Semi-solid Dosage Product and Services
Table 228. LEO Pharma Recent Developments
Table 229. Almirall, S.A Company Information
Table 230. Almirall, S.A Description and Overview
Table 231. Almirall, S.A Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 232. Almirall, S.A Semi-solid Dosage Product and Services
Table 233. Almirall, S.A Recent Developments
Table 234. Aclaris Therapeutics Company Information
Table 235. Aclaris Therapeutics Description and Overview
Table 236. Aclaris Therapeutics Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 237. Aclaris Therapeutics Semi-solid Dosage Product and Services
Table 238. Aclaris Therapeutics Recent Developments
Table 239. Taro Pharmaceutical Industries Company Information
Table 240. Taro Pharmaceutical Industries Description and Overview
Table 241. Taro Pharmaceutical Industries Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 242. Taro Pharmaceutical Industries Semi-solid Dosage Product and Services
Table 243. Taro Pharmaceutical Industries Recent Developments
Table 244. Teligent Pharma Company Information
Table 245. Teligent Pharma Description and Overview
Table 246. Teligent Pharma Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 247. Teligent Pharma Semi-solid Dosage Product and Services
Table 248. Teligent Pharma Recent Developments
Table 249. Perrigo Pharma Company Information
Table 250. Perrigo Pharma Description and Overview
Table 251. Perrigo Pharma Semi-solid Dosage Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 252. Perrigo Pharma Semi-solid Dosage Product and Services
Table 253. Perrigo Pharma Recent Developments
Table 254. Key Raw Materials Lists
Table 255. Raw Materials Key Suppliers Lists
Table 256. Semi-solid Dosage Distributors List
Table 257. Semi-solid Dosage Customers List
Table 258. Semi-solid Dosage Market Trends
Table 259. Semi-solid Dosage Market Drivers
Table 260. Semi-solid Dosage Market Challenges
Table 261. Semi-solid Dosage Market Restraints
Table 262. Research Programs/Design for This Report
Table 263. Key Data Information from Secondary Sources
Table 264. Key Data Information from Primary Sources
List of Figures
Figure 1. Semi-solid Dosage Product Picture
Figure 2. Global Semi-solid Dosage Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Semi-solid Dosage Market Share by Type in 2022 & 2034
Figure 4. Ointment Product Picture
Figure 5. Paste Product Picture
Figure 6. Plaster Product Picture
Figure 7. Gel Product Picture
Figure 8. Global Semi-solid Dosage Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 9. Global Semi-solid Dosage Market Share by Application in 2022 & 2034
Figure 10. Skin
Figure 11. Nasal Cavity
Figure 12. Vaginal Cavity
Figure 13. Rectal Cavity
Figure 14. Other
Figure 15. Semi-solid Dosage Report Years Considered
Figure 16. Global Semi-solid Dosage Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 17. Global Semi-solid Dosage Revenue 2018-2034 (US$ Million)
Figure 18. Global Semi-solid Dosage Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 19. Global Semi-solid Dosage Sales Quantity 2018-2034 (K Units)
Figure 20. Global Semi-solid Dosage Sales Quantity Market Share by Region (2018-2024)
Figure 21. Global Semi-solid Dosage Sales Quantity Market Share by Region (2024-2034)
Figure 22. North America Semi-solid Dosage Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. North America Semi-solid Dosage Revenue YoY (2018-2034) & (US$ Million)
Figure 24. Europe Semi-solid Dosage Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. Europe Semi-solid Dosage Revenue YoY (2018-2034) & (US$ Million)
Figure 26. China Semi-solid Dosage Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. China Semi-solid Dosage Revenue YoY (2018-2034) & (US$ Million)
Figure 28. APAC Semi-solid Dosage Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. APAC Semi-solid Dosage Revenue YoY (2018-2034) & (US$ Million)
Figure 30. Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity YoY (2018-2034) & (K Units)
Figure 31. Middle East, Africa and Latin America Semi-solid Dosage Revenue YoY (2018-2034) & (US$ Million)
Figure 32. The Top 10 and Top 5 Players Market Share by Semi-solid Dosage Sales Quantity in 2022
Figure 33. The Top 10 and Top 5 Players Market Share by Semi-solid Dosage Revenue in 2022
Figure 34. Semi-solid Dosage Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 35. Global Semi-solid Dosage Sales Quantity Market Share by Type (2018-2034)
Figure 36. Global Semi-solid Dosage Revenue Market Share by Type (2018-2034)
Figure 37. Global Semi-solid Dosage Sales Quantity Market Share by Application (2018-2034)
Figure 38. Global Semi-solid Dosage Revenue Market Share by Application (2018-2034)
Figure 39. North America Semi-solid Dosage Revenue Market Share by Company in 2022
Figure 40. North America Semi-solid Dosage Sales Quantity Market Share by Company in 2022
Figure 41. North America Semi-solid Dosage Sales Quantity Market Share by Type (2018-2034)
Figure 42. North America Semi-solid Dosage Revenue Market Share by Type (2018-2034)
Figure 43. North America Semi-solid Dosage Sales Quantity Market Share by Application (2018-2034)
Figure 44. North America Semi-solid Dosage Revenue Market Share by Application (2018-2034)
Figure 45. North America Semi-solid Dosage Revenue Share by Country (2018-2034)
Figure 46. North America Semi-solid Dosage Sales Quantity Share by Country (2018-2034)
Figure 47. United States Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 48. Canada Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 49. Europe Semi-solid Dosage Sales Quantity Market Share by Company in 2022
Figure 50. Europe Semi-solid Dosage Revenue Market Share by Company in 2022
Figure 51. Europe Semi-solid Dosage Sales Quantity Market Share by Type (2018-2034)
Figure 52. Europe Semi-solid Dosage Revenue Market Share by Type (2018-2034)
Figure 53. Europe Semi-solid Dosage Sales Quantity Market Share by Application (2018-2034)
Figure 54. Europe Semi-solid Dosage Revenue Market Share by Application (2018-2034)
Figure 55. Europe Semi-solid Dosage Revenue Share by Country (2018-2034)
Figure 56. Europe Semi-solid Dosage Sales Quantity Share by Country (2018-2034)
Figure 57. Germany Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 58. France Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 59. U.K. Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 60. Italy Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 61. Russia Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 62. China Semi-solid Dosage Sales Quantity Market Share by Company in 2022
Figure 63. China Semi-solid Dosage Revenue Market Share by Company in 2022
Figure 64. China Semi-solid Dosage Sales Quantity Market Share by Type (2018-2034)
Figure 65. China Semi-solid Dosage Revenue Market Share by Type (2018-2034)
Figure 66. China Semi-solid Dosage Sales Quantity Market Share by Application (2018-2034)
Figure 67. China Semi-solid Dosage Revenue Market Share by Application (2018-2034)
Figure 68. APAC Semi-solid Dosage Sales Quantity Market Share by Company in 2022
Figure 69. APAC Semi-solid Dosage Revenue Market Share by Company in 2022
Figure 70. APAC Semi-solid Dosage Sales Quantity Market Share by Type (2018-2034)
Figure 71. APAC Semi-solid Dosage Revenue Market Share by Type (2018-2034)
Figure 72. APAC Semi-solid Dosage Sales Quantity Market Share by Application (2018-2034)
Figure 73. APAC Semi-solid Dosage Revenue Market Share by Application (2018-2034)
Figure 74. APAC Semi-solid Dosage Revenue Share by Region (2018-2034)
Figure 75. APAC Semi-solid Dosage Sales Quantity Share by Region (2018-2034)
Figure 76. Japan Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 77. South Korea Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 78. China Taiwan Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 79. Southeast Asia Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 80. India Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 81. Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity Market Share by Company in 2022
Figure 82. Middle East, Africa and Latin America Semi-solid Dosage Revenue Market Share by Company in 2022
Figure 83. Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity Market Share by Type (2018-2034)
Figure 84. Middle East, Africa and Latin America Semi-solid Dosage Revenue Market Share by Type (2018-2034)
Figure 85. Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity Market Share by Application (2018-2034)
Figure 86. Middle East, Africa and Latin America Semi-solid Dosage Revenue Market Share by Application (2018-2034)
Figure 87. Middle East, Africa and Latin America Semi-solid Dosage Sales Quantity Share by Country (2018-2034)
Figure 88. Middle East, Africa and Latin America Semi-solid Dosage Revenue Share by Country (2018-2034)
Figure 89. Brazil Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 90. Mexico Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 91. Turkey Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 92. Israel Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 93. GCC Countries Semi-solid Dosage Revenue (2018-2034) & (US$ Million)
Figure 94. Semi-solid Dosage Value Chain
Figure 95. Semi-solid Dosage Production Process
Figure 96. Channels of Distribution (Direct Vs Distribution)
Figure 97. Distributors Profiles
Figure 98. Bottom-up and Top-down Approaches for This Report
Figure 99. Data Triangulation
Figure 100. Key Executives Interviewed